ERBB2 and breast cancer: When used as a single agent, trastuzumab is beneficial only in 15-30% of HER2/neu+ breast cancer patients that express very high levels of HER2/neu protein but efficacy can be enhanced when combined with chemotherapeutic drugs [18,21].